You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro ® (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should Mounjaro® (tirzepatide) be administered?
Administer Mounjaro once weekly, any time of day, with or without meals. Inject Mounjaro subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm. Rotate injection sites with each dose.
See important safety information, including boxed warning, in the attached prescribing information.
Administration of Mounjaro
Prior to initiation, train patients and their caregiver(s) on proper injection technique. A patient may self-inject if a healthcare provider determines that it is appropriate.
Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.
Administer MOUNJARO once weekly, any time of day, with or without meals.
Inject MOUNJARO subcutaneously in the abdomen, thigh, or another person should inject in the back of the upper arm.
Rotate injection sites with each dose.
Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.
When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.1
Enclosed Prescribing Information
Reference
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: January 12, 2026